Your browser doesn't support javascript.
loading
Use of Amplatzer vascular plugs and Amplatzer duct occluder II additional sizes for occlusion of patent ductus arteriosus: A multi-institutional study
VanLoozen, Dennis; Sandoval, Juan Pablo; Delaney, Jeffrey W; Pedra, Carlos; Calamita, Paulo; Dalvi, Bharat; Kenny, Damien; Cleary, Aoife; Amin, Zahid.
Afiliação
  • VanLoozen, Dennis; Augusta University. Department of Pediatric Cardiology, Children's Hospital of Georgia,. Augusta. US
  • Sandoval, Juan Pablo; Department of Pediatric Cardiology, Instituto Nacional de Cardiología Ignacio Chavez. Mexico City. MX
  • Delaney, Jeffrey W; Department of Pediatric Cardiology, University of Nebraska Medical Center/ Children's Hospital and Medical Center. Omaha. US
  • Pedra, Carlos; Department of pediatric cardiology, Instituto Dante Pazzanese de Cardiologia. São Paulo. BR
  • Calamita, Paulo; Department of pediatric cardiology, Instituto Dante Pazzanese de Cardiologia. São Paulo. BR
  • Dalvi, Bharat; Department of Cardiology, Glenmark Cardiac Centre, Mumbai. Maharashtra. IN
  • Kenny, Damien; Department of Cardiology and Cardiothoracic Surgery, Our Lady's Children's Hospital. Crumlin. IE
  • Cleary, Aoife; Department of Cardiology and Cardiothoracic Surgery, Our Lady's Children's Hospital. Crumlin. IE
  • Amin, Zahid; Augusta University. Department of Pediatric Cardiology, Children's Hospital of Georgia. Augusta. US
Catheter. cardiovasc. interv ; 92(7): 1323-1328, Dec. 2018. ilus, tab
Article em En | CONASS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1247634
Biblioteca responsável: BR79.1
ABSTRACT

BACKGROUND:

Variable patent ductus arteriosus (PDA) morphology and the need to close PDAs in small size patients has led physicians to use Amplatzer Vascular Plugs (AVP) and recently available Amplatzer Duct Occluder II - Additional Sizes (ADO II AS). The purpose of this study was to analyze the safety, efficacy, and complication rates of the ADO II AS and AVPs, specifically AVP II.

METHODS:

All patients undergoing PDA closure with an AVP or ADO II AS from 2011 to 2016 were included. Clinical, echocardiographic, and angiographic data were collected and reviewed.

RESULTS:

Four hundred and sixty-nine patients were included. Median age was 27 months (0.75­852) and the median weight was 11.4 kg (1­92). There were 51 patients ≤5 kg. Type A PDA was most common in 48% (n = 225), followed by type E (27.5%, n = 129), type D (13%, n = 61), type C (10.2%, n = 48), and type B (1.3%, n = 6). Devices included AVP II (n = 421), ADO II AS (n = 30), and AVP IV (n = 18), left pulmonary artery stenosis occurred in 4.3% (n = 20). One patient required surgery for severe stenosis; the remaining cases were mild and required no intervention. Device embolization occurred in 3 patients (10%) with the ADO II AS. Successful device closure was achieved in 98.9% of cases.

CONCLUSIONS:

The AVP II was highly effective for closing PDAs in smaller babies with varying morphologies and is safe when used in small sized patients with relatively low risk of complications. More studies are warranted to clarify the risks of ADO II AS.
Assuntos
Buscar no Google
Coleção SES: Producao_cientifica Base de dados: CONASS / SES-SP / SESSP-IDPCPROD Assunto principal: Cateterismo Cardíaco / Permeabilidade do Canal Arterial / Cardiopatias Congênitas Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Buscar no Google
Coleção SES: Producao_cientifica Base de dados: CONASS / SES-SP / SESSP-IDPCPROD Assunto principal: Cateterismo Cardíaco / Permeabilidade do Canal Arterial / Cardiopatias Congênitas Idioma: En Ano de publicação: 2018 Tipo de documento: Article